and storing the lyophilized and sealed product at 2-8°C.

13. The process according to claim 12, wherein the parameters used in the lyophilizing process are: freezing (-30 to -50°C), vacuum (20 to 100µbar), primary drying from -30 to -50°C (36 to 42h), and -5 to -10°C (18 to 24h) secondary drying 25 to 29°C (8 to 15h).

14. An attenuated tetravalent dengue vaccine that is produced by the process as described in any one of claims 1-13.

15. A process for preparing a tetravalent dengue vaccine for administration to a subject that comprises the step of reconstituting the sealed and lyophilized tetravalent dengue vaccine of claim 14 in a composition comprising 0.2M sodium phosphate monobasic dihydrate, 0.2M sodium phosphate dibasic heptahydrate, and water.

16. The process according to claim 15, wherein the sealed and lyophilized vaccine is reconstituted in 5 milliliters of the composition.

17. Use of the attenuated tetravalent dengue vaccine according to claim 14 in the preparation of a vaccine for inducing an immune response to virus dengue serotypes 1, 2, 3 and 4 in a subject, wherein the vaccine is for administering to the subject.

18. A tetravalent dengue vaccine kit that comprises the vaccine of claim 14, a reconstitution composition comprising 0.2M sodium phosphate monobasic dihydrate, 0.2M sodium phosphate dibasic heptahydrate and water.